TScan Therapeutics, Inc. announced that its Chief Financial Officer, Brian M. Silver, J.D., will be leaving the Company, effective July 21, 2023, to pursue a new opportunity at a leading advisory firm based in New York, where he lives with his family. Brian will continue to be available to provide strategic advice for the Company. The Company has initiated a search for a successor chief financial officer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.665 USD | +0.52% | +19.20% | +49.06% |
Apr. 19 | TScan Therapeutics Closes $150.1 Million Securities Offering | MT |
Apr. 17 | TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.06% | 493M | |
+22.88% | 42.68B | |
-2.94% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.88% | 24.94B | |
-19.78% | 18.96B | |
+29.43% | 12.3B | |
-3.19% | 11.95B | |
-2.36% | 11.55B |
- Stock Market
- Equities
- TCRX Stock
- News TScan Therapeutics, Inc.
- TScan Therapeutics, Inc. Announces Cessation of Brian M. Silver as Chief Financial Officer, Effective July 21, 2023